Efficacy

Zepzelca (Lurbinectedin) for Small Cell Lung Cancer

Zepzelca (lurbinectedin) is a medication specifically approved for the treatment of adults with metastatic small cell lung cancer (SCLC) that has progressed after prior platinum-based chemotherapy. Lurbinectedin is a selective inhibitor of oncogenic transcription and induces cell cycle arrest and apoptosis, which can lead to the death of cancer cells. The efficacy of Zepzelca was evaluated in a multicenter, single-arm, open-label clinical trial, which included a cohort of patients with SCLC who had disease progression on or after platinum-based chemotherapy.

The primary endpoint of the study was the overall response rate (ORR), which is the percentage of patients who experienced a significant reduction in tumor size. The results demonstrated that Zepzelca achieved an ORR of 35% with a median duration of response (DoR) of 5.3 months. These findings suggest that Zepzelca can provide a clinically meaningful response in a subset of patients with relapsed or refractory SCLC, although it is important to note that responses may vary and not all patients will experience the same level of benefit.

Retsevmo (Selpercatinib) for Non-Small Cell Lung Cancer

Retsevmo (selpercatinib) is a kinase inhibitor indicated for the treatment of non-small cell lung cancer (NSCLC) in patients with RET (rearranged during transfection) gene fusions, a rare driver of cancer growth. Selpercatinib targets and inhibits RET signaling pathways, which can be crucial for the survival and proliferation of cancer cells harboring RET gene alterations. The efficacy of Retsevmo for the treatment of NSCLC with RET gene fusions was assessed in a multicenter, open-label, multi-cohort clinical trial.

The trial's primary outcome measure was ORR, both in the treatment-naive and previously treated patients. The results indicated that Retsevmo demonstrated an ORR of 64% in treatment-naive patients and 56% in previously treated patients. The median DoR was not reached in treatment-naive patients and was 17.5 months in previously treated patients, indicating a durable response in a significant proportion of patients. These outcomes highlight Retsevmo's potential as a targeted therapy for NSCLC patients with RET gene fusions, offering a new avenue of treatment for this specific genetic alteration in lung cancer.